GlassScriptPhysician profile
Jennifer S Olson
NPI 1780198317
$3,800.15
in general payments reported to CMS, 2019-2025
29 companies · $546 in 2025
The $546 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,028 · 2022: $789 · 2023: $952 · 2024: $485 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,983.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,983.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $739.98 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $516.90 | 2021-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $411.06 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Abbvie INC. | $389.49 | 2021-2025 | |
| Dexcom, INC. | $382.26 | 2021-2023 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Janssen Biotech, INC. | $299.76 | 2022-2025 | Stelara, Tremfya, Remicade |
| Janssen Pharmaceuticals, INC | $205.09 | 2021-2023 | Xarelto |
| Genzyme Corporation | $145.75 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.24 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $63.50 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $59.89 | 2021-2022 | |
| Exact Sciences Corporation | $59.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.43 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $46.22 | 2023-2025 | Glassia, Eohilia |
| Ultragenyx Pharmaceutical INC. | $44.16 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $32.09 | 2021-2024 | Prolia, Evenity |
| Pfizer INC. | $32.08 | 2025 | |
| Ardelyx, INC. | $19.84 | 2024 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $19.47 | 2024 | |
| Mylan Specialty L.P. | $19.43 | 2023 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $19.02 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $17.50 | 2025 | Nexletol |
| Phathom Pharmaceuticals, INC. | $16.54 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $16.54 | 2023 | Eliquis |
| Neurelis, INC. | $16.11 | 2023 | Valtoco |
| Vertex Pharmaceuticals Incorporated | $14.68 | 2025 | |
| Seqirus USA INC | $13.07 | 2022 | |
| Ascensia Diabetes Care US INC. | $13.07 | 2021 | |
| Nestle Healthcare Nutrition INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.